Andreas G Frank
CIK 1529659 · View on SEC EDGAR ↗
Insider
First SEC filing: Jan. 13, 2023 · Latest: Jan. 13, 2023
On this page
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 28 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Oct. 11, 2024 | XRAY | A | 51 | $24.50 | $1,250 | 7,917 Direct | +0.65% | Acquired | -55.3% (price as of 2026-08-20) |
| Oct. 11, 2024 | XRAY | A | 392 | — | — | 119,865 Direct | +0.33% | Acquired | (price as of 2026-08-20) |
| July 12, 2024 | XRAY | A | 48 | $25.80 | $1,238 | 7,865 Direct | +0.61% | Acquired | -57.6% (price as of 2026-08-20) |
| July 12, 2024 | XRAY | A | 423 | — | — | 119,473 Direct | +0.36% | Acquired | (price as of 2026-08-20) |
| May 13, 2024 | XRAY | F | 2,452 | $28.18 | $69,097 | 118,814 Direct | -2.02% | Disposed | -61.2% (price as of 2026-08-20) |
| May 13, 2024 | XRAY | F | 12,118 | $28.18 | $341,485 | 121,266 Direct | -9.09% | Disposed | -61.2% (price as of 2026-08-20) |
| April 12, 2024 | XRAY | A | 40 | $31.45 | $1,258 | 7,817 Direct | +0.51% | Acquired | -65.2% (price as of 2026-08-20) |
| April 12, 2024 | XRAY | A | 504 | — | — | 133,384 Direct | +0.38% | Acquired | (price as of 2026-08-20) |
| March 18, 2024 | XRAY | A | 2,805 | $35.59 | $99,830 | 7,777 Direct | +56.42% | Acquired | -69.3% (price as of 2026-08-20) |
| March 4, 2024 | XRAY | A | 56,500 | — | — | 56,500 Direct | — | Acquired | (price as of 2026-08-20) |
| March 4, 2024 | XRAY | A | 16,902 | — | — | 132,880 Direct | +14.57% | Acquired | (price as of 2026-08-20) |
| March 1, 2024 | XRAY | F | 1,507 | $33.27 | $50,138 | 115,978 Direct | -1.28% | Disposed | -67.1% (price as of 2026-08-20) |
| Jan. 12, 2024 | XRAY | A | 19 | $36.80 | $699 | 4,972 Direct | +0.38% | Acquired | -70.3% (price as of 2026-08-20) |
| Jan. 12, 2024 | XRAY | A | 362 | — | — | 117,485 Direct | +0.31% | Acquired | (price as of 2026-08-20) |
| Nov. 16, 2023 | XRAY | F | 11,216 | $29.60 | $331,994 | 117,123 Direct | -8.74% | Disposed | -63.0% (price as of 2026-08-20) |
| Nov. 16, 2023 | XRAY | F | 2,458 | $29.60 | $72,757 | 128,339 Direct | -1.88% | Disposed | -63.0% (price as of 2026-08-20) |
| Oct. 13, 2023 | XRAY | A | 22 | $30.71 | $676 | 4,954 Direct | +0.45% | Acquired | -64.4% (price as of 2026-08-20) |
| Oct. 13, 2023 | XRAY | A | 534 | — | — | 130,797 Direct | +0.41% | Acquired | (price as of 2026-08-20) |
| July 14, 2023 | XRAY | A | 17 | $41.14 | $699 | 4,931 Direct | +0.35% | Acquired | -73.4% (price as of 2026-08-20) |
| July 14, 2023 | XRAY | A | 454 | — | — | 130,263 Direct | +0.35% | Acquired | (price as of 2026-08-20) |
| April 14, 2023 | XRAY | A | 461 | — | — | 129,809 Direct | +0.36% | Acquired | (price as of 2026-08-20) |
| April 10, 2023 | XRAY | A | 4,914 | $31.84 | $156,462 | 4,914 Direct | — | Acquired | -65.6% (price as of 2026-08-20) |
| March 3, 2023 | XRAY | A | 44,800 | — | — | 44,800 Direct | — | Acquired | (price as of 2026-08-20) |
| March 3, 2023 | XRAY | A | 14,520 | — | — | 129,348 Direct | +12.64% | Acquired | (price as of 2026-08-20) |
| Jan. 13, 2023 | XRAY | A | 449 | — | — | 114,828 Direct | +0.39% | Acquired | (price as of 2026-08-20) |
| Nov. 16, 2022 | XRAY | A | 51,400 | — | — | 51,400 Direct | — | Acquired | (price as of 2026-08-20) |
| Nov. 16, 2022 | XRAY | A | 16,340 | — | — | 114,379 Direct | +16.67% | Acquired | (price as of 2026-08-20) |
| Nov. 16, 2022 | XRAY | A | 98,039 | — | — | 98,039 Direct | — | Acquired | (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Oct. 11, 2024 | XRAY | Phantom Stock (Supplemental Executive Retirement Plan) SERP | Common Stock (51) | — | — | 51 | Acquired |
| July 12, 2024 | XRAY | Phantom Stock (Supplemental Executive Retirement Plan) SERP | Common Stock (48) | — | — | 48 | Acquired |
| April 12, 2024 | XRAY | Phantom Stock (Supplemental Executive Retirement Plan) SERP | Common Stock (40) | — | — | 40 | Acquired |
| March 18, 2024 | XRAY | Phantom Stock (Supplemental Executive Retirement Plan) SERP | Common Stock (2,805) | — | — | 2,805 | Acquired |
| March 4, 2024 | XRAY | Stock Option (Right to Buy) | Common Stock (56,500) | $33.28 | March 4, 2034 | 56,500 | Acquired |
| Jan. 12, 2024 | XRAY | Phantom Stock (Supplemental Executive Retirement Plan) SERP | Common Stock (19) | — | — | 19 | Acquired |
| Oct. 13, 2023 | XRAY | Phantom Stock (Supplemental Executive Retirement Plan) SERP | Common Stock (22) | — | — | 22 | Acquired |
| July 14, 2023 | XRAY | Phantom Stock (Supplemental Executive Retirement Plan) SERP | Common Stock (17) | — | — | 17 | Acquired |
| April 10, 2023 | XRAY | Phantom Stock (Supplemental Executive Retirement Plan) SERP | Common Stock (4,914) | — | — | 4,914 | Acquired |
| March 3, 2023 | XRAY | Stock Option (Right to Buy) | Common Stock (44,800) | $38.74 | March 3, 2023 | 44,800 | Acquired |
| Nov. 16, 2022 | XRAY | Stock Option (Right to Buy) | Common Stock (51,400) | $30.60 | Nov. 16, 2032 | 51,400 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
XRAY
Chief Business Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $721,479 | — | $1,811,457 | $562,877 | $529,620 | — | $121,275 | $3,746,708 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.